{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-093943","form_type":"8-K","ticker":"MGX","cik":"0001785279","company_name":"Metagenomi Therapeutics, Inc.","filed_at":"2026-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.169305+00:00","generated_at":"2026-05-15T19:47:56.931767+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Metagenomi reports $160.8M cash, MGX-001 on track for IND in 4Q 2026","bullets":["Cash, equivalents and marketable securities $160.8M as of Dec 31, 2025; runway through 4Q 2027.","R&D expenses $94.4M in FY2025 (down 13.6% from FY2024); G&A $26.8M (down 16.3% from $32.0M).","MGX-001 hemophilia A pre-IND meeting completed; IND filing expected 4Q 2026, clinical trials in 2027.","Preclinical NHP data showed curative FVIII levels; in vivo proof-of-concept for Antithrombin deficiency also achieved.","Corporate name changed to Metagenomi Therapeutics; Ionis collaboration advancing APOC3 target in cardiometabolic indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-093943","json":"https://secwatch.observer/filing/0001193125-26-093943.json","markdown":"https://secwatch.observer/filing/0001193125-26-093943.md","text":"https://secwatch.observer/filing/0001193125-26-093943.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526093943/0001193125-26-093943-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526093943/mgx-20260305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:47:56.931767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0425ca527f313abaaf5d573e20f50d05ba9cb3ed","claim":"Metagenomi Therapeutics, Inc. reported financial results for the full year ended December 31, 2025.","evidence_excerpt":"On March 5, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and additional business updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785279/000119312526093943/0001193125-26-093943-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}